FINHUB Insights

LLY · Q4 FY25 · Oct 1 – Dec 31, 2025

Eli Lilly Q4 FY25: where the revenue came from and where it went

Eli Lilly Q4 FY25: revenue $19.3B (+43% year over year). Net profit $6.6B. Largest cohort Product $18.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2025
Reported
Feb 12, 2026 10-K
Sankey diagram of Eli Lilly's income statement for Q4 FY25: revenue of $19.3 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$19.3B +43% year over year
Gross profit$15.9B 83% margin
Operating profit$8.4B 43% margin
Net profit$6.6B 34% margin

The numbers

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 19.3 100% +43%
Product 18.3 95% +52%
Collaboration and Other 1 5% −34%
Cost of revenue−3.418%
Gross profit15.983% margin+0pp
SG&A−3.116%−2pp
Other−4.423%+0pp
Operating profit8.443% margin+5pp
Tax−1.7
Interest & other costs−0.1
Net profit6.634%+2pp
Filing on EDGAR More quarters of LLY

Source of the numbers: structured XBRL data from the filing (10-K). The diagram is generated automatically and checked against EDGAR before release. The fourth quarter has no column of its own in an annual report, so it is the full year minus the first nine months. How we calculate it → About and methodology.

Older quarters